Arbutus Biopharma: IM-PROVE I Clinical Trial Demonstrated Undetectable HBsAg in 33% of Patients >ABUS
Arbutus Biopharma: IM-PROVE I Clinical Trial Demonstrated Undetectable HBsAg in 33% of Patients >ABUS
Arbutus Biopharma:Im-PROVE I临床试验显示33%的患者HBsAg检测结果不可检测>ABUS
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册